Dr. Didier Mandelbrot, M.D

NPI: 1295773596
Total Payments
$9,379
2022 Payments
$1,636
Companies
5
Transactions
20
Medicare Patients
1,697
Medicare Billing
$117,035

Payment Breakdown by Category

Other$4,900 (52.2%)
Travel$1,647 (17.6%)
Research$1,500 (16.0%)
Food & Beverage$865.33 (9.2%)
Consulting$466.67 (5.0%)

Payments by Nature

Nature of Payment Amount Transactions Share
Honoraria $4,900 3 52.2%
Travel and Lodging $1,647 7 17.6%
Unspecified $1,500 1 16.0%
Food and Beverage $865.33 8 9.2%
Consulting Fee $466.67 1 5.0%

Payments by Type

General
$7,879
19 transactions
Research
$1,500
1 transactions

Top Paying Companies

Company Total Records Latest Year
CSL Behring $6,894 13 $0 (2020)
ModernaTX, Inc. $1,500 1 $0 (2022)
ZOLL Medical Corporation $466.67 1 $0 (2020)
Novartis Pharmaceuticals Corporation $382.21 3 $0 (2017)
Takeda Pharmaceuticals U.S.A., Inc. $135.98 2 $0 (2022)

Payment History by Year

Year Amount Transactions Top Company
2022 $1,636 3 ModernaTX, Inc. ($1,500)
2020 $1,517 3 CSL Behring ($1,050)
2019 $4,794 5 CSL Behring ($4,794)
2018 $50.74 1 CSL Behring ($50.74)
2017 $1,382 8 CSL Behring ($999.46)

All Payment Transactions

20 individual payment records from CMS Open Payments

Date Company Product Nature Form Amount Type
07/01/2022 ModernaTX, Inc. Moderna Covid-19 Vaccine (Biological) Cash or cash equivalent $1,500.00 Research
Study: A Phase 3b, Open-Label, Safety and Immunogenicity Study of SARS CoV 2 mRNA-1273 Vaccine in Adult Solid Organ Transplant Recipients and Healthy Controls • Category: Infections and Infectious Diseases
06/07/2022 Takeda Pharmaceuticals U.S.A., Inc. Food and Beverage In-kind items and services $70.26 General
06/07/2022 Takeda Pharmaceuticals U.S.A., Inc. LIVTENCITY (Drug) Food and Beverage In-kind items and services $65.72 General
Category: IMMUNOLOGY
10/29/2020 CSL Behring Honoraria Cash or cash equivalent $700.00 General
10/07/2020 ZOLL Medical Corporation Consulting Fee Cash or cash equivalent $466.67 General
Category: DEFIBRILLATOR
06/30/2020 CSL Behring Honoraria Cash or cash equivalent $350.00 General
12/06/2019 CSL Behring Honoraria Cash or cash equivalent $3,850.00 General
12/06/2019 CSL Behring Travel and Lodging In-kind items and services $161.60 General
12/05/2019 CSL Behring Travel and Lodging In-kind items and services $573.49 General
12/05/2019 CSL Behring Travel and Lodging In-kind items and services $149.00 General
12/05/2019 CSL Behring Food and Beverage In-kind items and services $60.00 General
06/04/2018 CSL Behring Food and Beverage In-kind items and services $50.74 General
10/24/2017 CSL Behring Product in Development (Biological) Travel and Lodging Cash or cash equivalent $186.13 General
Category: Product in Development
10/11/2017 CSL Behring Product in Development (Biological) Travel and Lodging In-kind items and services $351.03 General
Category: Product in Development
10/11/2017 CSL Behring Product in Development (Biological) Food and Beverage In-kind items and services $191.65 General
Category: Product in Development
10/11/2017 CSL Behring Product in Development (Biological) Food and Beverage In-kind items and services $191.65 General
Category: Product in Development
10/11/2017 CSL Behring Product in Development (Biological) Travel and Lodging Cash or cash equivalent $79.00 General
Category: Product in Development
08/25/2017 Novartis Pharmaceuticals Corporation ZORTRESS (Drug) Food and Beverage In-kind items and services $123.64 General
Category: IMMUNOLOGY
08/24/2017 Novartis Pharmaceuticals Corporation ZORTRESS (Drug) Travel and Lodging In-kind items and services $146.90 General
Category: IMMUNOLOGY
08/24/2017 Novartis Pharmaceuticals Corporation ZORTRESS (Drug) Food and Beverage In-kind items and services $111.67 General
Category: IMMUNOLOGY

Research Studies & Clinical Trials

Study Name Company Amount Records
A Phase 3b, Open-Label, Safety and Immunogenicity Study of SARS CoV 2 mRNA-1273 Vaccine in Adult Solid Organ Transplant Recipients and Healthy Controls ModernaTX, Inc. $1,500 1

Medicare Billing by Year

Year Procedures Beneficiaries Services Submitted Medicare Paid
2023 9 294 532 $146,114 $22,189
2022 20 526 1,098 $255,821 $37,113
2021 15 413 800 $171,623 $26,688
2020 16 464 813 $187,957 $31,044
Total Patients
1,697
Total Services
3,243
Medicare Billing
$117,035
Procedure Codes
60

All Medicare Procedures & Services

60 procedure records from CMS Medicare Utilization — Page 1 of 3

HCPCS Description Setting Year Patients Services Charges Medicare Paid Ratio
99214 Established patient office or other outpatient visit, 30-39 minutes Facility 2023 144 173 $54,426 $11,344 20.8%
99233 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes Facility 2023 16 46 $18,621 $4,094 22.0%
99232 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes Facility 2023 20 39 $10,803 $2,247 20.8%
50200 Needle biopsy of kidney Facility 2023 24 25 $44,270 $2,069 4.7%
99238 Hospital discharge day management, 30 minutes or less Facility 2023 16 19 $6,555 $1,088 16.6%
36415 Insertion of needle into vein for collection of blood sample Office 2023 24 93 $3,255 $775.07 23.8%
76942 Ultrasonic guidance for needle placement Facility 2023 24 25 $2,697 $302.06 11.2%
85048 Automated white blood cell count Office 2023 13 56 $3,136 $139.44 4.4%
85014 Red blood cell concentration measurement Office 2023 13 56 $2,352 $129.92 5.5%
99214 Established patient office or other outpatient visit, 30-39 minutes Facility 2022 155 203 $59,682 $13,851 23.2%
99233 Follow-up hospital inpatient care per day, typically 35 minutes Facility 2022 38 117 $45,747 $8,948 19.6%
99232 Follow-up hospital inpatient care per day, typically 25 minutes Facility 2022 32 73 $20,221 $3,866 19.1%
50200 Needle biopsy of kidney Facility 2022 34 39 $69,030 $3,211 4.7%
99238 Hospital discharge day management, 30 minutes or less Facility 2022 27 28 $9,296 $1,517 16.3%
99215 Established patient office or other outpatient visit, 40-54 minutes Facility 2022 13 13 $6,097 $1,359 22.3%
90935 Hemodialysis procedure with physician evaluation Facility 2022 15 19 $11,210 $1,054 9.4%
99213 Established patient office or other outpatient visit, 20-29 minutes Facility 2022 17 18 $3,672 $859.35 23.4%
76942 Ultrasonic guidance for needle placement Facility 2022 32 37 $1,894 $403.85 21.3%
82565 Blood creatinine level Office 2022 17 79 $4,851 $397.36 8.2%
84132 Blood potassium level Office 2022 18 81 $4,374 $378.32 8.6%
36415 Insertion of needle into vein for collection of blood sample Office 2022 23 93 $3,069 $275.22 9.0%
82947 Blood glucose (sugar) level Office 2022 12 55 $2,761 $213.27 7.7%
85048 Automated white blood cell count Office 2022 18 82 $4,592 $204.43 4.5%
85014 Red blood cell concentration measurement Office 2022 18 82 $3,444 $190.78 5.5%
82570 Creatinine level to test for kidney function or muscle injury Office 2022 11 19 $1,488 $96.16 6.5%

About Dr. Didier Mandelbrot, M.D

Dr. Didier Mandelbrot, M.D is a Nephrology healthcare provider based in Madison, Wisconsin. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/02/2006. The National Provider Identifier (NPI) number assigned to this provider is 1295773596.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Didier Mandelbrot, M.D has received a total of $9,379 in payments from pharmaceutical and medical device companies, with $1,636 received in 2022. These payments were reported across 20 transactions from 5 companies. The most common payment nature is "Honoraria" ($4,900).

As a Medicare-enrolled provider, Mandelbrot has provided services to 1,697 Medicare beneficiaries, totaling 3,243 services with total Medicare billing of $117,035. Data is available for 4 years (2020–2023), covering 60 distinct procedure/service records.

Practice Information

  • Specialty Nephrology
  • Location Madison, WI
  • Active Since 06/02/2006
  • Last Updated 01/19/2021
  • Taxonomy Code 207RN0300X
  • Entity Type Individual
  • NPI Number 1295773596

Products in Payments

  • Moderna Covid-19 Vaccine (Biological) $1,500
  • Product in Development (Biological) $999.46
  • ZORTRESS (Drug) $382.21
  • LIVTENCITY (Drug) $65.72

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Nephrology Doctors in Madison